Choi Kyung-eun, CEO of STGenBio, Receives Commendation for Contributions to Employment Equality

STGEN Bio, a contract manufacturing organization (CMO) specialized in biopharmaceuticals under Dong-A Socio Holdings, announced on the 30th that CEO Choi Kyung-eun was selected as a contributor to gender employment equality and received a commendation from the Minister of Employment and Labor at the ‘2023 Employment Equality Contribution Awards.’

At the '2023 Employment Equality Contribution Awards' ceremony held on the 26th, Choi Kyung-eun, CEO of STGen Bio (left), is receiving an award from Lee Jeong-sik, Minister of Employment and Labor. [Photo by STGen Bio]

The Employment Equality Contribution Awards are hosted by the Ministry of Employment and Labor and are given to individuals and companies who have worked hard to establish employment equality and a culture of work-family balance in industrial workplaces. The ceremony, held on the 26th at the Korea Chamber of Commerce and Industry, was themed ‘Gender Coexistence Workplace, Sustainable Living Space,’ where outstanding cases of creating an employment environment and culture where men and women can work equally were presented, and contributors and excellent companies were honored.

CEO Choi Kyung-eun was honored for her efforts in practicing gender employment equality and supporting work-family balance through active communication with employees, implementing institutional improvements such as ▲resolving wage gaps through a fair compensation system ▲expanding the use of paid menstrual leave for female workers ▲granting congratulatory and condolence leave without distinction between maternal and paternal sides ▲carrying out activities to improve women’s human rights.

STGEN Bio was previously recognized as a family-friendly certified company in 2021 for establishing an excellent family-friendly management system and operating family-friendly policies that support work-family balance.

STGEN Bio, a biopharmaceutical CMO specialized business under Dong-A Socio Holdings, possesses production facilities with an 8,000ℓ capacity capable of manufacturing active pharmaceutical ingredients (DS) and prefilled syringe (PFS) production facilities capable of manufacturing finished pharmaceutical products (DP). The company is currently expanding its business area into contract development and manufacturing organization (CDMO) services.

CEO Choi Kyung-eun expressed her award acceptance remarks, saying, “STGEN Bio will continue to strive to be a company where all members respect each other, communicate, and grow together.”